Long-term medical treatment for Parkinson’s disease

被引:3
|
作者
John M. Bertoni
Jose-Luis Prendes
Pamela Sprenkle
机构
[1] Creighton University School of Medicine,Department of Neurology
关键词
Levodopa; Bromocriptine; Dopamine Agonist; Amantadine; Main Side Effect;
D O I
10.1007/s11940-001-0012-y
中图分类号
学科分类号
摘要
The authors of this paper view Parkinson’s disease (PD) as a clinically defined progressive syndrome of resting limb tremor, bradykinesia, muscle rigidity, and a shuffling unsteady gait that responds well to dopaminergic medications. Parkinson’s disease is a not a single entity, but rather a syndrome with diverse causes, with both genetic and environmental risk factors [1••]. The clinician’s concern is to rule out other entities, especially those having another specific treatment, and to give PD patients the best short- and long-term benefit, with the least possible unwanted side effects.
引用
收藏
页码:495 / 506
页数:11
相关论文
共 50 条
  • [31] Efficacy of multidisciplinary treatment program on long-term outcomes of individuals with Parkinson's disease
    Carne, William
    Cifu, David X.
    Marcinko, Paul
    Baron, Mark
    Pickett, Treven
    Qutubuddin, Abu
    Calabrese, Vincent
    Roberge, Peggy
    Holloway, Kathryn
    Mutchler, Brian
    [J]. JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2005, 42 (06): : 779 - 786
  • [32] Estimating the long-term effect of early levodopa treatment initiation in Parkinson's disease
    van der Heuvel, L.
    Krijthe, J.
    Evers, L.
    Meinders, M.
    Post, B.
    Heskes, T.
    Bloem, B.
    [J]. MOVEMENT DISORDERS, 2019, 34
  • [33] Open long-term treatment with rivastigmine in Parkinson's disease: report of six cases
    Hahn, K.
    Ebersbach, G.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (03) : XIV - XIV
  • [34] Short- and Long-Term Effect of Parkinson's Disease Multimodal Complex Treatment
    Heimrich, Konstantin G.
    Prell, Tino
    [J]. BRAIN SCIENCES, 2021, 11 (11)
  • [35] Motor and psychic complications in the long-term treatment of complicated Parkinson's disease with levodopa
    Molina, JA
    Jiménez-Jiménez, FJ
    Ortí-Pareja, M
    [J]. REVISTA DE NEUROLOGIA, 1999, 28 (10) : 982 - 990
  • [36] Workshop IV:: Drug treatment guidelines for the long-term management of Parkinson's disease
    Reichmann, H
    Sommer, U
    Fuchs, G
    Hefter, H
    Mark, G
    Müller, T
    Thümler, R
    Ulm, G
    Vieregge, P
    [J]. JOURNAL OF NEUROLOGY, 2000, 247 : 40 - 41
  • [37] Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson's Disease Psychosis
    Rashid, Nazia
    Shim, Andrew
    Andes, Sherry
    Quale, Sonja
    Abler, Victor
    [J]. JOURNAL OF APPLIED GERONTOLOGY, 2022, 41 (01) : 198 - 206
  • [38] Workshop IV: Drug treatment guidelines for the long-term management of Parkinson's disease
    H. Reichmann
    U. Sommer
    G. Fuchs
    H. Hefter
    G. Mark
    T. Müller
    R. Thümler
    G. Ulm
    P. Vieregge
    [J]. Journal of Neurology, 2000, 247 (Suppl 4) : IV40 - IV41
  • [39] Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease
    Mizuno, Yoshikuni
    Hattori, Nobutaka
    Kondo, Tomoyoshi
    Nomoto, Masahiro
    Origasa, Hideki
    Takahashi, Ryosuke
    Yamamoto, Mitsutoshi
    Yanagisawa, Nobuo
    [J]. CLINICAL NEUROPHARMACOLOGY, 2019, 42 (04) : 123 - 130
  • [40] Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
    Wolf, Elisabeth
    Seppi, Klaus
    Katzenschlager, Regina
    Hochschorner, Guenter
    Ransmayr, Gerhard
    Schwingenschuh, Petra
    Ott, Erwin
    Kloiber, Iris
    Haubenberger, Dietrich
    Auff, Eduard
    Poewe, Werner
    [J]. MOVEMENT DISORDERS, 2010, 25 (10) : 1357 - 1363